Jump to content

Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > legal

: Rx, Schedule IV (US)

or Rx-only

Use the filters below to narrow your results.

None (5) · Duloxetine (1) · Haloperidol (1)

Belsomra (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dayvigo (1) · Haldol, Serenace, Haldol Decanoate (1) · Quviviq (1) · Sunosi (1) · Zurzuvae (1)

Antidepressant (1) · Antiemetic (1) · Anxiolytic (1) · Dual orexin receptor antagonist (DORA) (3) · GABA-A positive allosteric modulator (oral) (1) · Neuroactive steroid (1) · Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) · SNRI (1) · the first approved (1) · Typical antipsychotic (1) · wake-promoting agent (1)

None (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · High-affinity D2 receptor antagonist (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1)

Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1) · Schizophrenia, acute psychosis, agitation, delirium, Tourette syndrome, severe nausea (1)

None (2) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1)

None (2) · 20 mg, 25 mg, 30 mg capsules (1) · 25 mg, 50 mg tablets (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · 75 mg, 150 mg tablets (1)

None (2) · 10 mg/d (1) · 150 mg/d (1) · 20 mg/d (1) · 50 mg/d (1) · 50 mg/d × 14 d (1)

IM (1) · IV (1) · Oral (7)

Day 3 of dosing in trials; sustained through day 45 (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PO 1–2 h; IM 30–60 min; IV 5–20 min (1) · ~30 min (3) · ~30-60 min (1)

12–24 h (oral); decanoate IM 3–4 weeks (1) · 14-day course; effect persists after discontinuation in trials (1) · Chronic daily dosing (1) · ~7-8 hours (3) · ~9 hours (1)

14–26 h (oral); ~3 weeks (decanoate) (1) · ~12 hours (2) · ~16-23 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~7.1 hours (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

Adequate (food-dependent, must take with fatty meal) (1) · ~44% (1) · ~50% (highly variable) (1) · ~60–70% (oral) (1) · ~62% (1) · ~82% (1) · ~95% (1)

Category C (2) · Limited data; avoid (3) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Limited data; pregnancy exposure registry available (1)

Showing below up to 7 results in range #1 to #7.

D

H

Haloperidol

L

Lemborexant

S

Z

Zuranolone

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"